IN 1995, the Cardiorenal Advisory Committee of the Food and Drug Administration, after a lengthy deliberation, unanimously decided that sublingual nifedipine should not officially be approved for the treatment of hypertensive emergencies. Despite this decision and despite authoritative voices1- 4 warning against this practice, the use of short-acting nifedipine for what was perceived as hypertensive emergencies remained widespread in the United States and all over the globe.
Messerli FH, Grossman E. The Use of Sublingual NifedipineA Continuing Concern. Arch Intern Med. 1999;159(19):2259-2260. doi:10.1001/archinte.159.19.2259